Cargando…
Ushering in the era of tRNA medicines
Long viewed as an intermediary in protein translation, there is a growing awareness that tRNAs are capable of myriad other biological functions linked to human health and disease. These emerging roles could be tapped to leverage tRNAs as diagnostic biomarkers, therapeutic targets, or even as novel m...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583094/ https://www.ncbi.nlm.nih.gov/pubmed/37703991 http://dx.doi.org/10.1016/j.jbc.2023.105246 |
_version_ | 1785122481230577664 |
---|---|
author | Anastassiadis, Theonie Köhrer, Caroline |
author_facet | Anastassiadis, Theonie Köhrer, Caroline |
author_sort | Anastassiadis, Theonie |
collection | PubMed |
description | Long viewed as an intermediary in protein translation, there is a growing awareness that tRNAs are capable of myriad other biological functions linked to human health and disease. These emerging roles could be tapped to leverage tRNAs as diagnostic biomarkers, therapeutic targets, or even as novel medicines. Furthermore, the growing array of tRNA-derived fragments, which modulate an increasingly broad spectrum of cellular pathways, is expanding this opportunity. Together, these molecules offer drug developers the chance to modulate the impact of mutations and to alter cell homeostasis. Moreover, because a single therapeutic tRNA can facilitate readthrough of a genetic mutation shared across multiple genes, such medicines afford the opportunity to define patient populations not based on their clinical presentation or mutated gene but rather on the mutation itself. This approach could potentially transform the treatment of patients with rare and ultrarare diseases. In this review, we explore the diverse biology of tRNA and its fragments, examining the past and present challenges to provide a comprehensive understanding of the molecules and their therapeutic potential. |
format | Online Article Text |
id | pubmed-10583094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Biochemistry and Molecular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-105830942023-10-19 Ushering in the era of tRNA medicines Anastassiadis, Theonie Köhrer, Caroline J Biol Chem JBC Reviews Long viewed as an intermediary in protein translation, there is a growing awareness that tRNAs are capable of myriad other biological functions linked to human health and disease. These emerging roles could be tapped to leverage tRNAs as diagnostic biomarkers, therapeutic targets, or even as novel medicines. Furthermore, the growing array of tRNA-derived fragments, which modulate an increasingly broad spectrum of cellular pathways, is expanding this opportunity. Together, these molecules offer drug developers the chance to modulate the impact of mutations and to alter cell homeostasis. Moreover, because a single therapeutic tRNA can facilitate readthrough of a genetic mutation shared across multiple genes, such medicines afford the opportunity to define patient populations not based on their clinical presentation or mutated gene but rather on the mutation itself. This approach could potentially transform the treatment of patients with rare and ultrarare diseases. In this review, we explore the diverse biology of tRNA and its fragments, examining the past and present challenges to provide a comprehensive understanding of the molecules and their therapeutic potential. American Society for Biochemistry and Molecular Biology 2023-09-12 /pmc/articles/PMC10583094/ /pubmed/37703991 http://dx.doi.org/10.1016/j.jbc.2023.105246 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | JBC Reviews Anastassiadis, Theonie Köhrer, Caroline Ushering in the era of tRNA medicines |
title | Ushering in the era of tRNA medicines |
title_full | Ushering in the era of tRNA medicines |
title_fullStr | Ushering in the era of tRNA medicines |
title_full_unstemmed | Ushering in the era of tRNA medicines |
title_short | Ushering in the era of tRNA medicines |
title_sort | ushering in the era of trna medicines |
topic | JBC Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583094/ https://www.ncbi.nlm.nih.gov/pubmed/37703991 http://dx.doi.org/10.1016/j.jbc.2023.105246 |
work_keys_str_mv | AT anastassiadistheonie usheringintheeraoftrnamedicines AT kohrercaroline usheringintheeraoftrnamedicines |